HELP Latest Headlines

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Helus Pharma (HELP) and Nektar Therapeutics (NKTR)

at www.tipranks.com (Thu, 23-Jul 1:50 AM)

Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Celldex (CLDX)

at www.tipranks.com (Wed, 22-Jul 6:50 AM)

Helus Pharma Advances Toward Phase 3 Results with Early Completion in Major MDD Trial—Durability and Remission Rates Underpin Optimism

Market Chameleon (Tue, 21-Jul 11:07 AM)

Helus Pharma Reaches Key Milestone: Early Enrollment Completion in Phase 3 Study Signals Progress for Novel Depression Treatment

Market Chameleon (Tue, 21-Jul 8:14 AM)

Helus Pharma Fast-Tracks Phase 3 Enrollment for MDD Drug HLP003

at www.tipranks.com (Tue, 21-Jul 5:51 PM)

Helus Pharma’s Phase 3 Enrollment Hits 86%: What Sets Its Breakthrough Depression Drug Apart Ahead of Crucial Q4 2026 Data?

Market Chameleon (Fri, 26-Jun 9:43 AM)

Helus Pharma Targets Major Depression With $50 Million Underwritten Offering—Funding Phase 3 HLP003 Data and Expansion

Market Chameleon (Thu, 25-Jun 10:35 AM)

Helus Pharma Raises $50 Million for Phase 3 Depression Drug as Underwritten Offering Priced at $4.85 per Share

Market Chameleon (Wed, 24-Jun 11:09 AM)

Helus Pharma’s $50 Million Offering Aims to Accelerate Key Mental Health Drug Trials

Market Chameleon (Wed, 24-Jun 7:06 AM)

Helus Pharma Highlights Progress in Mental Health Innovation with Milken Institute Conference Appearance

Market Chameleon (Thu, 30-Apr 8:02 AM)

Helus Pharma and TARA Mind Target Veteran Mental Health—Phase 3 Recruitment for HLP003 Ramps Up

Market Chameleon (Tue, 28-Apr 7:59 AM)